Immunohistochemistry of pulmonary biomarkers a perspective from members of the pulmonary pathology society
- Thunnissen, Erik
- Allen, Timothy Craig
- Adam, Julien
- Aisner, Dara L.
- Beasley, Mary Beth
- Borczuk, Alain C.
- Cagle, Philip T.
- Capelozzi, Vera Luiza
- Cooper, Wendy
- Hariri, Lida P.
- Kern, Izidor
- Lantuejoul, Sylvie
- Miller, Ross
- Mino-Kenudson, Mari
- Radonic, Teodora
- Raparia, Kirtee
- Rekhtman, Natasha
- Roy-Chowdhuri, Sinchita
- Russell, Prudence
- Schneider, Frank
- Sholl, Lynette M.
- Tsao, Ming Sound
- Vivero, Marina
- Yatabe, Yasushi
Publication date
January 2018
DOI Publisher
Archives of Pathology and Laboratory Medicine ISSN
0003-9985Abstract
The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly, and is relatively inexpensive. Pulmonary predictive biomarkers provide results essential for timely and accurate therapeutic decision making; for patients with metastatic non-small cell lung cancer, predictive immunohistochemistry includes ALK and programmed death ligand-1 (PD-L1) (ROS1, EGFR in Europe) testing. Handling along proper methodologic lines is needed to ensure patients receive the most accurate and representative test outcomes
Add to ORKG